Investigational drug · Phase 2
HLX79
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Membranous Nephropathy, Lupus Nephritis (LN).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "HLX79"
First trial start
2025
Aug 5, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX79", any sponsor or status.
Conditions studied
As listed on its trial records.
- Membranous Nephropathy
- Lupus Nephritis (LN)
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX79" as an intervention, largest first.
Shanghai Henlius BiotechIndustry
NCT07038382 · 24 participants (planned) · Start Aug 5, 2025 · Primary completion Jan 2027
Drug: HLX79 10mg/kg/Placebo+HLX01; HLX79 20mg/kg/Placebo + HLX01 and 1 more · For: Membranous Nephropathy; Lupus Nephritis (LN)
Sites: Beijing, China; Changsha, China; Guangzhou, China · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Membranous Nephropathy
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- HLX01Phase 21 trial
Shanghai Henlius Biotech · Membranous Nephropathy, Lupus Nephritis (LN)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.